Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




New Anticancer Drugs Interfere with DNA Binding Properties of EBV

By LabMedica International staff writers
Posted on 18 Mar 2019
The recent synthesis of small molecular drugs that interfere with the DNA binding properties of Epstein-Barr virus (EBV) suggests that it may be possible to develop medications for the treatment of EBV-associated cancers.

Persistent latent infection with EBV has been linked to development of various cancer types, including Burkitt’s lymphoma, nasopharyngeal carcinoma (NPC), and Hodgkin’s lymphoma. More...
The only viral protein that is consistently expressed in these tumors is Epstein-Barr nuclear antigen 1 (EBNA1), a multifunctional DNA binding protein critical for viral replication, genome maintenance, viral gene expression, and host cell survival. Since EBNA1 is the only viral protein consistently expressed in all EBV-associated tumors, it is an attractive target for therapeutic intervention.

To this end, investigators at the Wistar Institute (Philadelphia, PA, USA) used a fragment-based approach and x-ray crystallography to identify a 2,3-disubstituted benzoic acid series that selectively inhibited the DNA binding activity of EBNA1. They characterized these inhibitors biochemically and in cell-based assays, including chromatin immunoprecipitation and DNA replication assays.

The investigators reported in the March 6, 2019, online edition of the journal Science Translational Medicine that EBNA1 inhibitors demonstrated potent tumor growth suppressor activity in several EBV-dependent xenograft models, including patient-derived xenografts for NPC. These inhibitors selectively blocked EBV gene transcription and altered the cellular transforming growth factor-beta (TGF-beta) signaling pathway in NPC tumor xenografts.

Overall, the EBNA1-specific inhibitors showed favorable pharmacological properties and have the potential to be further developed for the treatment of EBV-associated cancers.

“EBNA1 is found in all EBV-associated tumors and does not look like any other protein in the human body,” said senior author Dr. Paul M. Lieberman, professor, of chemical biology and translational medicine at the Wistar Institute. “These characteristics, along with the protein’s particular structure, make EBNA1 a very attractive therapeutic target.”

Related Links:
Wistar Institute


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Drug Test Kit
DrugCheck 3000
New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.